Mouse behavioral genomics identifies Creld1 as a gatekeeper of somatosensation

This study establishes a postnatal CRISPR-Cas9 screening platform in mouse dorsal root ganglia to identify Creld1 as a master regulator of somatosensation that controls neuronal excitability by acting as an auxiliary subunit for Nav channels, thereby offering a novel therapeutic target for pain and itch.

The Gist

The Big Picture: A New Way to Find the "Volume Knobs" of Our Senses

Imagine your body is a high-tech security system. It has sensors everywhere (your skin) that detect touch, heat, cold, pain, and itch. These sensors send signals to your brain, which acts as the security command center.

For a long time, scientists knew about the main "sensors" (like Piezo2 for touch and TRPV1 for heat). But they were missing a huge piece of the puzzle: How do these signals get amplified and turned up loud enough for your brain to hear them?

This paper introduces a new, super-fast method to find the missing parts of this system and discovers a new "master switch" called Creld1 that controls the volume of almost all your senses.

---

1. The Problem: The "Baby" Bottleneck

Usually, to study a gene (a set of instructions in your DNA), scientists would delete it from a mouse's DNA before it was born.

• The Catch: If you delete a crucial gene too early, the mouse might die as a baby, or its body might grow in a weird way to compensate, hiding the gene's real job in adulthood.
• The Analogy: It's like trying to study how a car's engine works by removing the engine before the car is even built. You can't test the drive!

2. The Solution: The "Post-Baby" Knockout Tool

The researchers at Tsinghua University built a clever new tool. Instead of editing the mouse's DNA before birth, they waited until the mouse was a newborn (just a few days old) and injected a tiny virus (AAV9) into its brain.

• The Analogy: Think of this virus as a smart delivery drone. It flies into the mouse's nervous system and drops off a "scissor" package (CRISPR-Cas9) that specifically cuts out the instructions for a specific gene only in the sensory nerves of the back.
• Why it's cool: The mouse grows up normally, but as an adult, it suddenly loses that specific gene. This lets scientists see exactly what that gene does in a fully grown animal without the "baby death" problem.

3. The Discovery: Finding the "Master Switch"

Using this new drone-delivery method, the team tested 20 different genes they thought might be important for feeling things.

• The Result: Most of the genes didn't change how the mice felt things. But one gene, Creld1, was a total game-changer.
• The "Creld1" Effect:
  • When they cut it out (Knockout): The mice became almost numb. They didn't feel gentle touches, didn't flinch from hot plates, didn't react to pinpricks, and didn't even scratch when itched. They were like a security system with the power cord pulled.
  • When they added extra (Overexpression): The mice became super-sensitive. A light brush felt like a scratch; a warm room felt like a fire. The volume was cranked up to 11.

4. How It Works: The "Volume Knob" Analogy

So, what does Creld1 actually do?

• The Mechanism: Your nerves use tiny channels called Sodium Channels (Nav) to send electrical signals. Think of these channels as the volume knobs on a stereo.
• Creld1's Job: Creld1 is a protein that attaches to these volume knobs.
  • Without Creld1: The volume knob is stuck at "Mute." Even if the sensor (touch/heat) is triggered, the signal is too weak to reach the brain.
  • With Creld1: It turns the knob up. It makes the channels open more easily and send stronger signals.
• The Twist: The researchers found that Creld1 doesn't just turn up the volume for one type of sound (like just pain). It turns up the volume for everything: touch, heat, cold, and itch. It's a Master Volume Control for your entire somatosensory system.

5. The Human Connection: Why Don't We Feel Numb?

The researchers looked at the human version of this gene (CRELD1).

• The Surprise: Humans have different "versions" (isoforms) of this gene.
  • Some versions (like in mice) have a special "tail" that lets them grab the volume knobs and turn them up.
  • Other human versions have a broken or different tail, so they can't grab the knobs.
• The Implication: This might explain why humans with mutations in CRELD1 often have heart or brain issues but don't seem to be completely numb to pain like the mice were. Different versions of the gene might handle the "volume" differently in different parts of our body.

Summary

This paper is a breakthrough for two reasons:

1. The Tool: They invented a fast, safe way to test genes in adult animals, bypassing the "baby death" problem.
2. The Discovery: They found Creld1, a protein that acts like a Master Volume Knob for our sense of touch, pain, heat, and itch.

Why does this matter?
If we can understand how to tweak this "volume knob," we might be able to create new drugs that turn down the volume for chronic pain or itch without turning off the whole system (which would make you numb). It's a potential new path to treating pain that doesn't rely on heavy opioids.

Technical Summary

1. Problem Statement

Somatosensation (touch, temperature, pain, and itch) relies on primary sensory neurons in the dorsal root ganglion (DRG). While key molecular sensors like PIEZO2 (touch) and TRPV1 (heat) and downstream effectors like Nav1.7 (voltage-gated sodium channel) have been identified, the full repertoire of molecular regulators governing these sensory modalities remains incomplete.

• Limitations of Current Methods: Traditional germline knockout approaches often fail to identify genes essential for adult somatosensation due to:
  • Perinatal lethality: Knocking out critical genes (e.g., Nav1.7, Creld1) often kills the embryo or neonate, preventing behavioral analysis in adults.
  • Developmental compensation: Other genes may compensate for the loss during development, masking the gene's specific role in adult function.
  • Low throughput: Systematic screening of DRG-expressed genes using conventional methods is slow and costly.

2. Methodology

The authors developed a robust postnatal CRISPR-Cas9 knockout platform to screen DRG-expressed genes in adult mice without the confounding factors of embryonic lethality or developmental compensation.

• In Vivo Gene Knockout Strategy:

  • Viral Delivery: Intracerebroventricular (ICV) injection of AAV9 viruses carrying sgRNAs targeting specific genes into neonatal mice (P0–P2) expressing Cas9 (ROSA26-Cas9 knock-in mice).
  • Targeting: The virus efficiently infects DRG neurons (approx. 70–78% of subpopulations) while sparing the brain and spinal cord, allowing for specific gene ablation in sensory neurons.
  • Validation: The platform was first validated by knocking out known genes (Trpv1, Piezo2, Nav1.7) and confirming expected molecular reductions (mRNA/protein) and specific behavioral deficits (e.g., loss of heat sensitivity in Trpv1 KO, loss of touch in Piezo2 KO).

• Genomic Screen:

  • A targeted screen of 20 candidate genes expressed in DRG neurons was performed. Candidates included subtype markers (e.g., Pvalb, Tac1) and membrane proteins (e.g., Stoml3, Creld1).
  • Mice were subjected to a comprehensive battery of behavioral assays 8 weeks post-injection, covering:
    • Touch: Von Frey filaments, brush stimulation.
    • Pain: Pinprick, Randall-Selitto (mechanical), Hot/Cold plate (thermal).
    • Itch: Histamine-dependent and independent (chloroquine, compound 48/80) scratching.
    • Controls: Body weight, rotarod (motor coordination), open field (locomotion).

• Mechanistic Investigations:

  • Conditional Knockout (cKO): Generated Creld1 floxed mice crossed with Advillin-CreERT2 to induce tamoxifen-dependent, DRG-specific deletion, confirming that the phenotype is DRG-specific and not due to systemic effects.
  • Electrophysiology: Whole-cell patch-clamp recordings in DRG neurons and heterologous systems (HEK293T, ND-7/23) to measure sodium currents ($I_{Na}$), action potential firing, and voltage dependence.
  • Biochemistry: Co-immunoprecipitation (Co-IP), mass spectrometry, GST pull-downs, and cell-surface biotinylation to identify protein interactions and localization.
  • Structure-Function Analysis: Tested various Creld1 mutants (domain deletions, disease-associated mutations) and human isoforms to determine the structural basis of function.

3. Key Contributions

1. Novel Screening Platform: Established a high-efficiency, postnatal CRISPR-Cas9 screening method that overcomes embryonic lethality and developmental compensation, enabling the functional characterization of genes essential for adult somatosensation.
2. Discovery of Creld1: Identified Cysteine-rich with EGF-like domains 1 (Creld1) as a master regulator of somatosensation, a role previously unknown.
3. Mechanistic Insight: Defined Creld1 as a novel auxiliary regulator of voltage-gated sodium channels (Nav), specifically modulating Nav1.6, Nav1.7, and Nav1.8.
4. Evolutionary Divergence: Revealed that human CRELD1 exhibits isoform-dependent regulation of Nav1.7 due to sequence divergence in the C-terminal transmembrane domain, potentially explaining the lack of reported somatosensory defects in human CRELD1 mutation carriers compared to mice.

4. Key Results

• Phenotypic Validation of the Platform:

  • Postnatal Trpv1 KO abolished heat sensitivity; Piezo2 KO abolished gentle touch; Nav1.7 KO caused broad deficits in pain, temperature, and itch. These phenotypes matched or exceeded those of traditional conditional KOs, validating the platform.

• Creld1 as a Pan-Sensory Regulator:

  • Behavioral Deficits: Creld1 knockout (both sgRNA-mediated and cKO) resulted in profound deficits across all tested modalities: reduced sensitivity to gentle touch, mechanical pain, thermal pain (hot/cold), and both histamine-dependent and independent itch.
  • Specificity: Unlike Trpv1 or Piezo2 (modality-specific), Creld1 loss affected all sensory types, suggesting a downstream, general mechanism.
  • Overexpression: Conversely, overexpressing Creld1 in DRG neurons potentiated sensory responses (lower thresholds for touch and heat), confirming a gain-of-function effect.

• Molecular Mechanism:

  • Interaction: Creld1 physically interacts with Nav channels (Nav1.6, 1.7, 1.8) via its C-terminal transmembrane (TM) domain.
  • Functional Modulation:
    • Knockout: Reduced Nav current density by ~89% in DRG neurons, increased rheobase (threshold for firing), and reduced action potential firing rates.
    • Overexpression: Increased Nav current density and induced a hyperpolarizing shift in activation voltage (making neurons more excitable).
    • Trafficking: Creld1 does not affect surface expression/trafficking of Nav channels but modulates their biophysical gating properties.
  • Domain Requirement: Deletion of the C-terminal TM domain (ΔTM) abolished both the interaction with Nav1.7 and the functional potentiation of currents.

• Human Isoform Divergence:

  • Human CRELD1 has five isoforms. Isoforms 2 and 4 retain the conserved C-terminal TM domain and can regulate Nav1.7 (similar to mouse).
  • Isoforms 1, 3, and 5 have divergent C-terminal domains and fail to interact with or regulate Nav1.7. This suggests that the "master regulator" function seen in mice may be diluted or absent in humans depending on isoform expression, explaining why human CRELD1 mutations (linked to heart defects and epilepsy) do not typically present with somatosensory loss.

5. Significance

• Therapeutic Potential: The discovery that Creld1 acts as a "gatekeeper" for neuronal excitability via Nav channels offers a new target for pain and itch treatment. Modulating the Creld1-Nav interface could provide a precision approach to dampen hyperexcitability (pain/itch) without the broad side effects of direct Nav channel blockers.
• Gene Therapy: The study demonstrates that postnatal manipulation of Creld1 levels in specific DRG subtypes can alleviate or enhance sensory perception, opening avenues for gene therapy in chronic pain or sensory deficits.
• Methodological Impact: The postnatal CRISPR screening platform provides a scalable framework for systematically identifying the "missing links" in sensory biology, particularly for genes that are lethal when knocked out embryonically.
• Evolutionary Biology: The findings highlight a striking evolutionary divergence between mouse and human sensory regulation, suggesting that the robust somatosensory control by Creld1 in mice may not be fully conserved in humans, necessitating careful clinical evaluation of CRELD1 patients for subtle sensory phenotypes.